Pfizer · NSE: PFIZER · BSE: 500680
Q2 FY26 results · Jul–Sep 2025
Pfizer reported revenue from operations of ₹642.34 crore (up 9.1% from Q2 FY25) and net profit of ₹189.02 crore (up 19.4% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a standalone basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 642.34 | 588.59 | +9.1% | 603.05 | +6.5% |
| Other income | 41.85 | 43.07 | −2.8% | 67.17 | −37.7% |
| Total income | 684.19 | 631.66 | +8.3% | 670.22 | +2.1% |
| Profit before tax | 255.37 | 215.23 | +18.6% | 259.53 | −1.6% |
| Net profit for the period | 189.02 | 158.35 | +19.4% | 191.75 | −1.4% |
| EPS, basic (₹) | 41.32 | 34.61 | +19.4% | 41.91 | −1.4% |
| Net margin (%) | 29.4 | 26.9 | 31.8 |
Standalone
- Filed with BSE
- 26 Nov 2025, 15:00 IST
- Board meeting
- 12 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE